Haemonetics Total Assets from 2010 to 2024

HAE Stock  USD 85.43  0.51  0.60%   
Haemonetics' Total Assets are increasing over the years with slightly volatile fluctuation. Overall, Total Assets are expected to go to about 2.3 B this year. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals
 
Total Assets  
First Reported
1991-06-30
Previous Quarter
2.5 B
Current Value
2.5 B
Quarterly Volatility
602.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Haemonetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Haemonetics' main balance sheet or income statement drivers, such as Interest Expense of 15.4 M, Total Revenue of 1.4 B or Gross Profit of 710.4 M, as well as many indicators such as Price To Sales Ratio of 4.27, Dividend Yield of 0.0098 or PTB Ratio of 5.13. Haemonetics financial statements analysis is a perfect complement when working with Haemonetics Valuation or Volatility modules.
  
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.

Latest Haemonetics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Haemonetics over the last few years. Total assets refers to the total amount of Haemonetics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Haemonetics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Haemonetics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Haemonetics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 2.2 B10 Years Trend
Slightly volatile
   Total Assets   
       Timeline  

Haemonetics Total Assets Regression Statistics

Arithmetic Mean1,464,782,837
Geometric Mean1,292,616,075
Coefficient Of Variation36.48
Mean Deviation382,123,959
Median1,461,871,000
Standard Deviation534,286,840
Sample Variance285462.4T
Range2.2B
R-Value0.82
Mean Square Error99651.8T
R-Squared0.68
Significance0.0002
Slope98,216,235
Total Sum of Squares3996474T

Haemonetics Total Assets History

20242.3 B
20232.2 B
20221.9 B
20211.9 B
20201.8 B
20191.3 B
20181.3 B

Other Fundumenentals of Haemonetics

Haemonetics Total Assets component correlations

0.640.870.30.910.60.960.740.050.95-0.570.530.910.970.530.28-0.830.920.740.59-0.33-0.560.690.190.68-0.45
0.640.30.670.610.870.460.870.120.54-0.850.590.390.530.77-0.05-0.380.390.450.4-0.55-0.280.360.210.190.23
0.870.3-0.020.710.340.950.510.010.89-0.180.530.960.930.370.61-0.920.960.730.61-0.15-0.580.70.160.73-0.44
0.30.67-0.020.230.410.060.3-0.190.34-0.540.110.10.250.3-0.370.040.12-0.230.3-0.170.19-0.030.32-0.330.01
0.910.610.710.230.710.840.70.110.76-0.60.540.740.820.60.27-0.620.770.740.34-0.35-0.550.640.280.66-0.45
0.60.870.340.410.710.480.850.130.42-0.780.660.390.460.810.14-0.330.40.570.21-0.56-0.380.40.290.330.19
0.960.460.950.060.840.480.680.060.93-0.370.510.960.980.420.43-0.920.960.80.63-0.24-0.590.760.120.8-0.45
0.740.870.510.30.70.850.680.210.61-0.720.610.580.660.650.12-0.650.580.70.51-0.56-0.370.570.020.540.19
0.050.120.01-0.190.110.130.060.21-0.03-0.20.36-0.180.00.20.26-0.11-0.190.23-0.4-0.380.030.12-0.26-0.140.19
0.950.540.890.340.760.420.930.61-0.03-0.420.450.910.980.380.29-0.870.930.610.7-0.19-0.430.630.220.59-0.46
-0.57-0.85-0.18-0.54-0.6-0.78-0.37-0.72-0.2-0.42-0.54-0.25-0.4-0.690.170.27-0.27-0.34-0.090.750.35-0.070.04-0.080.0
0.530.590.530.110.540.660.510.610.360.45-0.540.430.460.850.71-0.530.420.580.12-0.75-0.520.21-0.020.220.17
0.910.390.960.10.740.390.960.58-0.180.91-0.250.430.950.350.43-0.91.00.690.74-0.13-0.550.710.150.79-0.45
0.970.530.930.250.820.460.980.660.00.98-0.40.460.950.410.34-0.890.960.70.69-0.2-0.50.730.180.69-0.47
0.530.770.370.30.60.810.420.650.20.38-0.690.850.350.410.41-0.320.350.610.12-0.63-0.650.30.210.230.21
0.28-0.050.61-0.370.270.140.430.120.260.290.170.710.430.340.41-0.490.410.490.07-0.23-0.430.290.020.31-0.01
-0.83-0.38-0.920.04-0.62-0.33-0.92-0.65-0.11-0.870.27-0.53-0.9-0.89-0.32-0.49-0.89-0.71-0.70.30.46-0.630.1-0.710.26
0.920.390.960.120.770.40.960.58-0.190.93-0.270.421.00.960.350.41-0.890.70.72-0.11-0.560.720.20.78-0.49
0.740.450.73-0.230.740.570.80.70.230.61-0.340.580.690.70.610.49-0.710.70.35-0.25-0.760.770.190.84-0.11
0.590.40.610.30.340.210.630.51-0.40.7-0.090.120.740.690.120.07-0.70.720.350.08-0.160.550.110.54-0.03
-0.33-0.55-0.15-0.17-0.35-0.56-0.24-0.56-0.38-0.190.75-0.75-0.13-0.2-0.63-0.230.3-0.11-0.250.080.310.160.510.01-0.17
-0.56-0.28-0.580.19-0.55-0.38-0.59-0.370.03-0.430.35-0.52-0.55-0.5-0.65-0.430.46-0.56-0.76-0.160.31-0.42-0.1-0.610.26
0.690.360.7-0.030.640.40.760.570.120.63-0.070.210.710.730.30.29-0.630.720.770.550.16-0.420.340.79-0.16
0.190.210.160.320.280.290.120.02-0.260.220.04-0.020.150.180.210.020.10.20.190.110.51-0.10.340.09-0.1
0.680.190.73-0.330.660.330.80.54-0.140.59-0.080.220.790.690.230.31-0.710.780.840.540.01-0.610.790.09-0.31
-0.450.23-0.440.01-0.450.19-0.450.190.19-0.460.00.17-0.45-0.470.21-0.010.26-0.49-0.11-0.03-0.170.26-0.16-0.1-0.31
Click cells to compare fundamentals

About Haemonetics Financial Statements

Haemonetics stakeholders use historical fundamental indicators, such as Haemonetics' Total Assets, to determine how well the company is positioned to perform in the future. Although Haemonetics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Haemonetics' assets and liabilities are reflected in the revenues and expenses on Haemonetics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Haemonetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Assets2.2 B2.3 B
Intangibles To Total Assets 0.44  0.30 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Haemonetics is a strong investment it is important to analyze Haemonetics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Haemonetics' future performance. For an informed investment choice regarding Haemonetics Stock, refer to the following important reports:
Check out the analysis of Haemonetics Correlation against competitors.
For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.375
Earnings Share
2.41
Revenue Per Share
26.77
Quarterly Revenue Growth
0.086
Return On Assets
0.0588
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.